Liang‐Liang Ding

497 total citations
28 papers, 343 citations indexed

About

Liang‐Liang Ding is a scholar working on Endocrinology, Diabetes and Metabolism, Molecular Biology and Surgery. According to data from OpenAlex, Liang‐Liang Ding has authored 28 papers receiving a total of 343 indexed citations (citations by other indexed papers that have themselves been cited), including 20 papers in Endocrinology, Diabetes and Metabolism, 14 papers in Molecular Biology and 10 papers in Surgery. Recurrent topics in Liang‐Liang Ding's work include Diabetes Treatment and Management (20 papers), Metabolism, Diabetes, and Cancer (10 papers) and Diabetes Management and Research (7 papers). Liang‐Liang Ding is often cited by papers focused on Diabetes Treatment and Management (20 papers), Metabolism, Diabetes, and Cancer (10 papers) and Diabetes Management and Research (7 papers). Liang‐Liang Ding collaborates with scholars based in China, United States and Israel. Liang‐Liang Ding's co-authors include Mei Qiu, Hairong Zhou, Shu-Yan Liu, Miao Zhang, Wei Xu-bin, Wei Wei, Xiang Tan, Xueyan Duan, Dehua Wang and Wei Yang and has published in prestigious journals such as PLoS ONE, The Journal of Clinical Endocrinology & Metabolism and Medicine.

In The Last Decade

Liang‐Liang Ding

27 papers receiving 337 citations

Peers

Liang‐Liang Ding
June K.Y. Li China
Ilan Yanuv Israel
Aliza Rozenberg Israel
Andrea Lage United States
Christina Stahre Sweden
Anne M. Lovejoy United States
Shih‐Chen Tung Taiwan
Yoshikazu Hiura Japan
Takafumi Majima Japan
D Teale United Kingdom
June K.Y. Li China
Liang‐Liang Ding
Citations per year, relative to Liang‐Liang Ding Liang‐Liang Ding (= 1×) peers June K.Y. Li

Countries citing papers authored by Liang‐Liang Ding

Since Specialization
Citations

This map shows the geographic impact of Liang‐Liang Ding's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Liang‐Liang Ding with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Liang‐Liang Ding more than expected).

Fields of papers citing papers by Liang‐Liang Ding

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Liang‐Liang Ding. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Liang‐Liang Ding. The network helps show where Liang‐Liang Ding may publish in the future.

Co-authorship network of co-authors of Liang‐Liang Ding

This figure shows the co-authorship network connecting the top 25 collaborators of Liang‐Liang Ding. A scholar is included among the top collaborators of Liang‐Liang Ding based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Liang‐Liang Ding. Liang‐Liang Ding is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Qiu, Mei, Liang‐Liang Ding, Miao Zhang, & Hairong Zhou. (2021). Safety of four SGLT2 inhibitors in three chronic diseases: A meta-analysis of large randomized trials of SGLT2 inhibitors. Diabetes and Vascular Disease Research. 18(2). 1476853704–1476853704. 62 indexed citations
2.
Qiu, Mei, Liang‐Liang Ding, & Hairong Zhou. (2021). Effects of SGLT2 inhibitors on cardiovascular and renal outcomes in type 2 diabetes. Medicine. 100(10). e25121–e25121. 14 indexed citations
3.
Qiu, Mei, et al.. (2021). Impact of time factor and patient characteristics on the efficacy of PCI vs CABG for left main coronary disease. Medicine. 100(10). e25057–e25057. 3 indexed citations
4.
Qiu, Mei, Liang‐Liang Ding, & Hairong Zhou. (2021). Comparative Efficacy of Five SGLT2i on Cardiorenal Events: A Network Meta-analysis Based on Ten CVOTs. American Journal of Cardiovascular Drugs. 22(1). 69–81. 7 indexed citations
5.
6.
Ding, Liang‐Liang, et al.. (2021). Comprehensive analysis of the safety of semaglutide in type 2 diabetes: a meta-analysis of the SUSTAIN and PIONEER trials. Endocrine Journal. 68(6). 739–742. 24 indexed citations
7.
Qiu, Mei, et al.. (2021). Meta-Analysis of the Effects of Four Factors on the Efficacy of SGLT2 Inhibitors in Patients with HFrEF. ESC Heart Failure. 8(2). 1722–1724. 2 indexed citations
8.
Zhao, Limin, et al.. (2021). Sotagliflozin Reduces HF Events in T2DM Regardless of Baseline Characteristics, Including HF, CKD and LVEF. Cardiovascular Drugs and Therapy. 35(5). 1077–1078. 3 indexed citations
9.
10.
Qiu, Mei, Liang‐Liang Ding, & Hairong Zhou. (2021). Factors affecting the efficacy of SGLT2is on heart failure events: a meta-analysis based on cardiovascular outcome trials. Cardiovascular Diagnosis and Therapy. 11(3). 699–706. 3 indexed citations
11.
Ding, Liang‐Liang, et al.. (2021). Meta-Analysis on the Safety and Cardiorenal Efficacy of SGLT2 Inhibitors in Patients Without T2DM. Frontiers in Cardiovascular Medicine. 8. 690529–690529. 12 indexed citations
12.
13.
Ding, Liang‐Liang, et al.. (2020). Osteoporosis drugs for prevention of clinical fracture in white postmenopausal women: a network meta-analysis of survival data. Osteoporosis International. 31(5). 961–971. 17 indexed citations
14.
15.
16.
Qiu, Mei, Liang‐Liang Ding, Wei Xu-bin, Wei Wei, & Hairong Zhou. (2020). Effects of glucagon-like peptide 1 receptor agonists and sodium glucose cotransporter 2 inhibitors on major adverse cardiovascular events in type 2 diabetes by race, ethnicity, and region. Medicine. 99(49). e23489–e23489. 9 indexed citations
17.
Qiu, Mei, Liang‐Liang Ding, Miao Zhang, & Hairong Zhou. (2020). Comparison of the risk of SGLT2is and NonSGLT2is in leading to amputation: A network meta-analysis. Journal of Diabetes and its Complications. 35(2). 107803–107803. 6 indexed citations
18.
Qiu, Mei, et al.. (2020). Meta-regression analysis of the efficacy of alendronate for prevention of glucocorticoid-induced fractures. Medicine. 99(42). e22690–e22690. 1 indexed citations
19.
20.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by June K.Y. Li Breakdown of academic impact, for papers by Ilan Yanuv Breakdown of academic impact, for papers by Aliza Rozenberg Breakdown of academic impact, for papers by Andrea Lage Breakdown of academic impact, for papers by Christina Stahre Breakdown of academic impact, for papers by Anne M. Lovejoy Breakdown of academic impact, for papers by Shih‐Chen Tung Breakdown of academic impact, for papers by Yoshikazu Hiura Breakdown of academic impact, for papers by Takafumi Majima Breakdown of academic impact, for papers by D Teale
Rankless by CCL
2026